The Global Gastrointestinal Stromal Tumors Therapeutics Market is expected to grow by $1.08 bn during 2022-2026, accelerating at a CAGR of 5.97% during the forecast period
October 24, 2022 11:23 ET
|
ReportLinker
New York, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gastrointestinal Stromal Tumors Therapeutics Market 2022-2026" -...
24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight
October 19, 2022 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- 24+ Key Companies Actively Working in the Gastrointestinal Stromal Tumor Pipeline Segment | DelveInsight Gastrointestinal stromal tumors (GISTs) are...
Immunicum AB: Immunicum tillkännager Corporate Rebranding och namnbyte till Mendus AB
June 23, 2022 02:58 ET
|
Immunicum AB
Varumärkestransformationen återspeglar framstegen inom nästa generations cancerimmunterapier, den kommande tillverkningsexpansionen och företagets långsiktiga ambitionerBolagets aktie fortsätter att...
Immunicum AB: Immunicum Announces Corporate Rebranding and Name Change to Mendus AB
June 23, 2022 02:58 ET
|
Immunicum AB
Rebranding reflects advancing pipeline in next generation cancer immunotherapies, upcoming manufacturing expansion, and long-term corporate aspirationsThe Company’s stock to continue trading under...
Immunicum AB: Immunicum har erhållit FDA-beteckning för särläkemedel för ilixadencel som behandling av gastrointestinala stromacellstumörer (GIST)
June 09, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (“ Immunicum ” publ ; IMMU.ST), ett bioläkemedelsföretag fokuserat på tumörrecidiv och svårbehandlade etablerade tumörer , meddelade idag att man har beviljats en Orphan Drug Designation...
Immunicum AB: Immunicum Received FDA Orphan Drug Designation for Ilixadencel as Treatment of Gastrointestinal Stromal Tumors (GIST)
June 09, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (“Immunicum” publ; IMMU.ST), a biopharmaceutical company focused on tumor recurrence and hard-to-treat established tumors, announced today that it has been granted an Orphan Drug...
Immunicum AB: Immunicum deltar i kommande konferenser
June 01, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (“Immunicum” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på behandlingar mot tumörrecidiv och svårbehandlade etablerade tumörer, tillkännagav idag sitt deltagande i följande...
Immunicum AB: Immunicum to Participate in Upcoming Conferences
June 01, 2022 02:00 ET
|
Immunicum AB
Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following...
Immunicum AB: Immunicum tillkännager positiva interimsresultat från ADVANCE II-studie i AML-underhållsbehandling
May 16, 2022 02:00 ET
|
Immunicum AB
Analys av primärstudiens effektmått slutfördes med 7 patienter som visade ett mätbar restsjukdom (MRD)-svar, varav 5 patienter konverterade från MRD+ till MRD- och 2 patienter som visade en avsevärd,...
Immunicum AB: Immunicum Announces Positive Interim Results from ADVANCE II Study in AML Maintenance Treatment
May 16, 2022 02:00 ET
|
Immunicum AB
Analysis of primary study endpoint was completed with 7 patients showing a measurable residual disease (MRD) response, of which 5 patients converted from MRD+ to MRD- and 2 patients showed a...